Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

Inclusion Criteria: * Completed Study GEN-003-003 * Received all 3 GEN-003 doses (any dose combination) in Study GEN-003-003 * Received last dose of GEN-003 within 11 to 18 months prior * Reported data in the daily electronic reporting period on at least 80% of days in Study GEN-003-003 * Collected at least 45 swabs (of 56 total expected swabs) during the Month 11 to 12 swab collection period in Study GEN-003-003 * Willing and able to provide written informed consent * Willing to perform and comply with all study procedures * Postmenopausal or willing to practice a highly effective method of contraception for 28 days before and 90 days after enrollment Exclusion Criteria: * Did not meet all eligibility criteria in Study GEN-003-003, or received incorrect treatment in Study GEN-003-003 * Use of suppressive antiviral medication within 14 days prior * Use of topical steroids or antiviral medication in the anogenital region within 14 days prior * Use of tenofovir, lysine, or other medication or supplement known or purported to affect HSV recurrence frequency or intensity within 14 days prior * History of any form of ocular HSV infection, HSV-related erythema multiforme, or herpes meningitis or encephalitis * Immunocompromised individuals * Diagnosis or suspicion of an AESI * Diagnosis or suspicion of any other autoimmune disease not listed in Appendix 4 of the protocol * Vaccine-related SAE in GEN-003-003 * Known current infection with HIV or hepatitis B or C virus * History of hypersensitivity to any component of the vaccine * Prior receipt of another vaccine containing HSV-2 antigens other than GEN-003 * Receipt of any IP within 30 days prior to the maintenance dose of GEN-003/placebo * Receipt of any blood product within 90 days prior to the maintenance dose * Receipt of a live vaccine within 28 days prior to or any other vaccine within 14 days prior to maintenance dose * Planned use of any vaccine from the maintenance dose to 28 days after the maintenance dose * Pregnant or nursing women * History of drug or alcohol abuse * Other active, uncontrolled comorbidities * Changes to medication used to manage an underlying comorbidity within 60 days prior